2019


2018


2017


Itchins, M., Clarke, S., Pavlakis, N. (2018). Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)? - the shifting paradigm of therapeutics. Translational Lung Cancer Research, 7(Suppl 1), S39-S45. [More Information]


Information]</a> 

2017


2016


Vaccaro, L., Johnson, S., Kiely, B., Clayton, J., Clarke, S.,


Clarke, S. (2013). An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin TM ) [ASCENT]. 2012 COSA 39th Annual Scientific Meeting.


**2013**


Clarke, S. (2013). An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin TM ) [ASCENT]. 2012 COSA 39th Annual Scientific Meeting.


Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ça change, plus ça ne change pas!). *Translational Gastrointestinal Cancer*, 28(1), 44-46. 


2012
advanced cancer patients. European Society of Medical Oncology 2012 Congress.


Clarke, S. (2012). Translational research at the Kolling Institute of Medical Research. 5th Annual Hunter Cancer Research Symposium.


2011


2009


2008


2007


2005


2004


2003


Saw, R., Morgan, M., Koorey, D., Painter, D., Findlay, M.,


2002


2000


2001


